CN Patent

CN119751465A — 螺环化合物

Assigned to C4 Therapeutics Inc · Expires 2025-04-04 · 1y expired

What this patent protects

本发明提供了化合物和中间体。本发明还提供了与普遍表达的E3连接酶蛋白cereblon(CRBN)结合的化合物，及其用于治疗异常细胞增殖的用途。本发明还提供了可用作用于靶向蛋白降解的双功能化合物的合成中的合成中间体的化合物。

USPTO Abstract

本发明提供了化合物和中间体。本发明还提供了与普遍表达的E3连接酶蛋白cereblon(CRBN)结合的化合物，及其用于治疗异常细胞增殖的用途。本发明还提供了可用作用于靶向蛋白降解的双功能化合物的合成中的合成中间体的化合物。

Drugs covered by this patent

gilteritinib-fumarate (GILTERITINIB FUMARATE)

Patent Metadata

Patent number: CN119751465A
Jurisdiction: CN
Classification: —
Expires: 2025-04-04
Drug substance claim: No
Drug product claim: No
Assignee: C4 Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.